Impact of landmark responses on 3-year (yr) outcomes with ponatinib in heavily pretreated CP-CML patients (pts).

被引：0

作者：

Muller, Martin C.

Baccarani, Michele

Deininger, Michael W. N.

Guilhot, Francois

Hochhaus, Andreas

Hughes, Timothy P.

Shah, Neil P.

Talpaz, Moshe

Lustgarten, Stephanie

Rivera, Victor M.

Clackson, Timothy Piers

Haluska, Frank G.

Cortes, Jorge E.

机构：

[1] Univ Med Mannheim, Mannheim, Germany

[2] S Orsola Malpighi Univ Hosp, Bologna, Italy

[3] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA

[4] CHU Poitiers, Inserm CIC 1402, Poitiers, France

[5] Jena Univ Hosp, Jena, Germany

[6] South Australian Hlth & Med Res Inst, Adelaide, SA, Australia

[7] Univ Adelaide, Adelaide, SA, Australia

[8] Univ Calif San Francisco, San Francisco, CA 94143 USA

[9] Univ Michigan, Ann Arbor, MI 48109 USA

[10] ARIAD Pharmaceut Inc, Cambridge, MA 02139 USA

[11] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期

关键词：

D O I：

10.1200/JCO.2016.34.15_suppl.7053

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

7053

引用

页数：4

共 50 条

[1] LANDMARK ANALYSES IN THE PIVOTAL PONATINIB PACE TRIAL: IMPACT OF EARLY RESPONSES ON 3-YEAR OUTCOMES IN HEAVILY PRETREATED CP-CML PATIENTS
Mueller, M.
Baccarani, M.
Deininger, M. W.
Guilhot, F.
Hochhaus, A.
Hughes, T. P.
Shah, N. P.
Talpaz, M.
Lustgarten, S.
Rivera, V. M.
Clackson, T.
Haluska, F. G.
Cortes, J. E.
HAEMATOLOGICA, 2016, 101 : 239 - 239
[2] RESPONSES AT EARLY LANDMARK TIME POINTS ARE ASSOCIATED WITH OUTCOMES IN HEAVILY PRETREATED CP-CML PATIENTS (PTS) TREATED WITH PONATINIB
Mueller, M.
Baccarani, M.
Deininger, M. W.
Guilhot, F.
Hochhaus, A.
Hughes, T. P.
Shah, N. P.
Talpaz, M.
Lustgarten, S.
Rivera, V. M.
Clackson, T.
Haluska, F. G.
Cortes, J. E.
HAEMATOLOGICA, 2015, 100 : 65 - 65
[3] Impact of early landmark responses with ponatinib on 4-yr outcomes in CP-CML patients (pts) in PACE, a pivotal phase II trial.
Mueller, Martin
Baccarani, Michele
Deininger, Michael W. N.
Guilhot, Francois
Hochhaus, Andreas
Hughes, Timothy P.
Shah, Neil P.
Talpaz, Moshe
Lustgarten, Stephanie
Santillana, Sergio
Rivera, Victor M.
Clackson, Timothy Piers
Cortes, Jorge E.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[4] Five-year results of the ponatinib phase II PACE trial in heavily pretreated CP-CML patients (pts).
Kantarjian, Hagop M.
Pinilla-Ibarz, Javier
Le Coutre, Philipp D.
Paquette, Ronald
Chuah, Charles
Nicolini, Franck E.
Apperley, Jane
Khoury, Hanna Jean
Talpaz, Moshe
Baccarani, Michele
Lustgarten, Stephanie
Santillana, Sergio
Guilhot, Francois
Deininger, Michael W. N.
Hochhaus, Andreas
Hughes, Timothy P.
Shah, Neil P.
Cortes, Jorge E.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[5] Achieving Early Landmark Response Is Predictive of Outcomes in Heavily Pretreated Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib
Mueller, Martin C.
Baccarani, Michele
Deininger, Michael W.
Guilhot, Francois
Hochhaus, Andreas
Hughes, Timothy P.
Shah, Neil P.
Talpaz, Moshe
Lustgarten, Stephanie
Rivera, Victor M.
Clackson, Tim
Haluska, Frank G.
Cortes, Jorge E.
BLOOD, 2014, 124 (21)
[6] 5-YR RESULTS FROM THE PIVOTAL PHASE 2 PONATINIB PACE TRIAL: EFFICACY, SAFETY AND LANDMARK ANALYSIS IN HEAVILY PRETREATED PATIENTS (PTS) WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML)
Cortes, J. E.
Kantarjian, H. M.
Pinilla-Ibarz, J.
le Coutre, P. D.
Paquette, R.
Chuah, C.
Nicolini, F. E.
Apperley, J. F.
Khoury, H. J.
Talpaz, M.
Baccarani, M.
Guilhot, F.
Deininger, M. W.
Hochhaus, A.
Hughes, T. P.
Shah, N. P.
Lustgarten, S.
Santillana, S.
Rivera, V. M.
Clackson, T.
Mueller, M. C.
HAEMATOLOGICA, 2017, 102 : 236 - 237
[7] Early Cytogenetic or Molecular Landmark Response to Ponatinib Treatment Predicts Outcomes in Heavily Pretreated Patients With Chronic-Phase Chronic Myeloid Leukemia (CP-CML) in PACE: 5-Year Data
Mueller, Martin C.
Cortes, Jorge
Chuah, Charles
DeAngelo, Daniel J.
Deininger, Michael
Guilhot, Francois
Hughes, Timothy
Nicolini, Franck E.
Pinilla-Ibarz, Javier
Rea, Delphine
Rosti, Gianantonio
Shah, Neil P.
Talpaz, Moshe
Lu, Vickie
Padukkavidana, Thihan
Kantarjian, Hagop M.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S336 - S337
[8] Ponatinib In Heavily Pretreated Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML): Management Of Adverse Events (AEs)
Le Coutre, Philipp D.
Kim, Dong-Wook
Pinilla-Ibarz, Javier
Paquette, Ronald
Chuah, Charles
Nicolini, Franck E.
Apperley, Jane F.
Khoury, H. Jean
Talpaz, Moshe
Dipersio, John F.
DeAngelo, Daniel J.
Abruzzese, Elisabetta
Rea, Delphine
Baccarani, Michele
Muller, Martin C.
Gambacorti-Passerini, Carlo
Lustgarten, Stephanie
Yanase, Kumiko
Turner, Christopher D.
Haluska, Frank G.
Guilhot, Francois
Deininger, Michael W.
Hochhaus, Andreas
Hughes, Timothy P.
Goldman, John M.
Shah, Neil P.
Kantarjian, Hagop M.
Cortes, Jorge E.
BLOOD, 2013, 122 (21)
[9] EPIC: A Phase 3 Trial of Ponatinib Compared With Imatinib in CP-CML Patients
Lipton, Jeffrey H.
Chuah, Charles
Guerci-Bresler, Agnes
Rosti, Gianantonio
Simpson, David
Lustgarten, Stephanie
Rivera, Victor M.
Clackson, Tim
Haluska, Frank G.
Baccarani, Michele
Cortes, Jorge E.
Guilhot, Francois
Hochhaus, Andreas
Hughes, Timothy P.
Kantarjian, Hagop
Shah, Neil P.
Talpaz, Moshe
Deininger, Michael W.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 : S211 - S211
[10] PONATINIB EFFICACY AND SAFETY IN HEAVILY PRETREATED LEUKEMIA PATIENTS: 3-YEAR RESULTS OF THE PACE TRIAL
Cortes, J.
Kim, D. W.
Pinilla-Ibarz, J.
le Coutre, P. D.
Paquette, R.
Chuah, C.
Nicolini, F. E.
Apperley, J. F.
Khoury, H. J.
Talpaz, M.
DiPersio, J. F.
DeAngelo, D. J.
Abruzzese, E.
Rea, D.
Baccarani, M.
Mueller, M. C.
Gambacorti-Passerini, C.
Lustgarten, S.
Rivera, V. M.
Clackson, T.
Haluska, F. G.
Guilhot, F.
Deininger, M. W.
Hochhaus, A.
Hughes, T. P.
Shah, N. P.
Kantarjian, H. M.
HAEMATOLOGICA, 2015, 100 : 64 - 64

← 1 2 3 4 5 →